Atezolizumab-associated retinopathy
B. Obtain information about the immunotherapy protocol initiated for her sarcoma
The clinical presentation of this patient is compatible with retinal toxicity associated with atezolizumab, an immune checkpoint inhibitor that targets the programmed death ligand 1.1 Checkpoint inhibitors are increasingly being used to treat metastatic malignancies, and their risk of inducing uveitis is well recognized among ophthalmologists.2 However, atezolizumab can also cause a specific form of retinopathy,1,3 which on optical coherence tomography and near infrared imaging demonstrates features similar to those observed with acute macular neuroretinopathy, with hyperreflective changes at the outer plexiform and outer nuclear layers that colocalize on near infrared to dark areas in addition to venulitis and small intraretinal cystic spaces, which are not typical features of acute macular neuroretinopathy.4